

LC-QTOF-MS BASED TARGETED AND UNTARGETED METABOLOMIC APPROACHES FOR THE IDENTIFICATION OF POTENTIAL BIOMARKERS IN PLASMA FROM PEDIATRICS WITH CHRONIC KIDNEY DISEASE

S. Benito¹, A. Sánchez², N. Unceta¹, F. Andrade³, L. Aldámiz-Echevarria³, M.A. Goicolea¹, R.J. Barrio¹


¹ Department of Analytical Chemistry, University of the Basque Country (UPV/EHU), Faculty of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain

² Central Service of Analysis (SGiker), University of the Basque Country (UPV/EHU), Laskaray Ikerunea, Miguel de Unamuno 3, 01006 Vitoria-Gasteiz, Spain

³ Group of Metabolism, BioCruces Health Research Institute, CIBER de Enfermedades Raras (CIBERER), Plaza de Cruces 12, 48903 Barakaldo, Spain

INTRODUCTION

Chronic kidney disease (CKD) is a major worldwide public health problem which causes several disturbances due to an irreversible kidney damage which can progress to renal hypofunction. However, information available for CKD in both pediatric and adult population is limited. As a result, CKD is difficult to diagnose, to follow in progression and to evaluate the response to therapy.



- "Classic biomarker" in clinical practice
- Lacks sensitivity and reveals kidney damage when an important nephronic loss has already taken place

NEW BIOMARKERS TO BE USED IN PEDIATRICS ARE NEEDED

- DNA
- RNA
- Proteins
- **Metabolites**

OMICS

Useful sciences for finding new potential biomarkers:

- Genomics
- Transcriptomics
- Proteomics
- **Metabolomics**

METABOLOMICS

Corresponds to the study of small molecules, typically below 1500 Da, in a biological system.

Metabolite levels are considered the ultimate response of biological systems to genetic or environmental changes.

TARGETED METABOLOMICS

- Determination and quantification of known metabolites, suspicious to be altered in a disease
- More complex and specific sample treatment and analytical method

DIFFERENT APPROACHES

UNTARGETED METABOLOMICS

- Measurement and comparison of as many metabolites as possible without bias in control and disease groups to find unknown metabolites to be used as new potential biomarkers
- General and more simple sample treatment and analytical method

EXPERIMENTAL



TARGETED METABOLOMICS

- 32 CKD samples
- 24 control samples
- * Calibration samples
- + QC samples



Plasma samples:


- 32 from CKD pediatrics (3-18 y)
- 29 from control pediatrics (6-19 y)

Aliquoted and divided for different sample treatments


UNTARGETED METABOLOMICS

- 32 CKD samples
- 26 control samples
- * QC samples

Information available: age, sex, CKD stage, treatment (not treated, dialyzed, transplanted)



- **Development and validation** of an ion-pairing LC-QTOF-MS methodology
- Quantification of **16 metabolites** from the **arginine-creatine metabolic pathway**, **arginine methylation** and **urea cycle** in plasma using analytical standards
- **Univariate and multivariate analysis** of the results to find significantly altered metabolites in CKD in comparison with control patients
- **Published work:**
Benito S, Sánchez A, Unceta N, Andrade F, Aldámiz-Echevarria L, Goicolea MA, Barrio RJ. *Anal Bioanal Chem.* 2016; 408(3):747-60.



- **Development** of a reverse-phase LC-QTOF-MS methodology
- Measured **as many entities as possible**
- There is **no need for analytical standards** (except for identification/confirmation)
- **Workflow:** data pre-processing (noise filtering, peak detection, peak alignment), data analysis (chemometric and statistical analysis to find unknown metabolites whose levels are statistically different in control and CKD pediatrics) and identification of entities using different databases, MS/MS fragmentation analysis and identity confirmation by means of analytical standards.

RESULTS AND CONCLUSIONS

- **Targeted metabolomics approach:** Univariate analysis showed that glycine, citrulline, creatinine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) were significantly increased for CKD pediatric patients. Similarly, regarding multivariate analysis, S-adenosylhomocysteine, SDMA, creatinine, citrulline, S-adenosylmethionine (SAM), ADMA, glutathione, dimethylglycine and glycine were found to be increased in pediatrics with CKD. Moreover, PCA showed that both groups are well separated and it is possible to predict the early stages of the disease with a more than 10 % better accuracy in comparison with the use of creatinine only including these analytes.
- **Untargeted metabolomics approach:** Around 15 entities were found to be significant after doing data pre-processing and subsequent data analysis. Identification of these entities using different databases and MS/MS fragmentation analysis is being performed.

ACKNOWLEDGEMENTS

The authors thank for technical and human support provided by SGiker of UPV/EHU and European funding (ERDF and ESF) as well as the Division of Metabolism belonging to Cruces University Hospital (Barakaldo, Spain) for supplying real samples for this study. This work was funded by the Department of Industry, Innovation, Commerce and Tourism of the Basque Government (SAI 12/25 Project) and by the Basque Government, Research Groups of the Basque University System (Project No. IT338-10). The Basque Government is also gratefully acknowledged for a predoctoral grant (PRE_2013_1_899) and for a mobility grant (EP_2016_1_0003) for Sandra Benito (Department of Education, Language Policy and Culture). This grant made possible doing an stay in Chemometrics group in the Analytical Chemistry Department at Radboud University, which is also thanked for the opportunity given.